Skip to main content

Table 1 Distribution of mutant HIV-1 isolates by inhibitor susceptibility

From: Sequence and structure based models of HIV-1 protease and reverse transcriptase drug resistance

 

Isolate Phenotypes (%) a

 

Drug

S

I

R

Total

 

Protease Inhibitors

 

Amprenavir (APV)

63

26

11

495

Atazanavir (ATV)

49

29

22

200

Indinavir (IDV)

53

26

21

502

Lopinavir (LPV)

46

22

32

320

Nelfinavir (NFV)

39

28

33

526

Ritonavir (RTV)

50

20

30

473

Saquinavir (SQV)

61

18

21

509

Tipranavir (TPV)

78

11

11

47

 

Nucleoside/Nucleotide RT Inhibitors

 

Lamivudine (3TC)

29

18

53

244

Abacavir (ABC)

28

45

27

237

Zidovudine (AZT)

50

23

27

240

Stavudine (d4T)

53

36

11

242

Zalcitabine (ddC)

39

52

9

161

Didanosine (ddI)

51

43

6

243

Emtricitabine (FTC)

31

13

56

52

Tenofovir (TDF)

65

25

10

167

 

Nonnucleoside RT Inhibitors

 

Delavirdine (DLV)

53

20

27

304

Efavirenz (EFV)

53

22

25

296

Nevirapine (NVP)

43

11

46

307

  1. a S, sensitive; I, intermediate; R, resistant. Category thresholds are discussed in Methods.